We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2011 by Vancouver Coastal Health.
Recruitment status was:  Not yet recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01373736
First Posted: June 15, 2011
Last Update Posted: June 15, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Vancouver Coastal Health
June 13, 2011
June 15, 2011
June 15, 2011
Not Provided
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
Not Provided
The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.
Not Provided
Interventional
Phase 3
Primary Purpose: Diagnostic
  • Pheochromocytoma
  • Neuroblastoma
  • Paraganglioma
  • Medullary Thyroid Carcinoma
  • Carcinoid Tumors
Drug: 123I-meta-iodobenzylguanidine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Subjects must have a clinical indication for 123I-MIBG imaging to evaluate for the presence, extent, or status of neuroendocrine tumors;
  • subjects must be able and willing to comply with study procedures.

Exclusion Criteria:

  • Subjects with history of renal insufficiency (serum creatinine level > 3.0 mg/dL [265 µmol/L]) and inability to be withdrawn from medications known to interfere with 123I-MIBG uptake;
  • Subjects unable to tolerate lying supine;
  • Subjects pregnant or breastfeeding, unless the information to be gained outweighs the possible hazardous effects of 123I-MIBG administration. Where the assessment of the risk/benefit ration suggests the use of 123I-MIBG in nursing mothers, the breastfeeding should be discontinued for at least 48 hours post-injection.
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT01373736
H10-02695
Yes
Not Provided
Not Provided
Daniel Worsley, Vancouver Coastal Health
Vancouver Coastal Health
Not Provided
Principal Investigator: Daniel Worsley, MD Vancouver Coastal Health
Vancouver Coastal Health
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP